Agustin Mohedas, Ph.D.
Agustin Mohedas is a Portfolio Manager and Research Analyst on the Health Care Team at Janus Henderson Investors. He is focused primarily on the biotechnology sector. Before joining the firm as a research analyst in 2019, Agustin was a senior analyst at Eventide Asset Management, working on the Healthcare and Life Sciences Fund from 2017. Prior to this, he was an analyst with RA Capital Management, a long/short hedge fund focused on biotechnology, from 2014.
Agustin received his bachelor of science degree in biomedical engineering from Texas A&M University, graduating summa cum laude. He also earned a PhD in medical engineering and medical physics from the Harvard-MIT Program in Health Sciences and Technology. His PhD research focused on drug development for a rare genetic disease, resulting in multiple patents and publications. He has 9 years of financial industry experience.
Products Managed
Articles Written
Keeping perspective on AI’s role in biotech
While technology is an important aspect of drug discovery, the value of new medicines – and the firms developing them – comes down to the quality of clinical data.
Biopharma’s targeted approach to growth
A new drug targeting a common mutation found in tumors represents a breakthrough in cancer therapy and a potential new source of growth for biopharma.